Supercritical fluid processing of drug nanoparticles in stable suspension

Journal of Nanoscience and Nanotechnology

Volumn 7, Issue 7, 2007, Pages 2542-2545

  Pathak, Pankaj ^a   Meziani, Mohammed J ^a   Desai, Tarang ^a   Foster, Charles ^a   Diaz, Julian A ^a   Sun, Ya Ping ^a  

^a CLEMSON UNIVERSITY   (United States)

Author keywords

Amphotericin B; Drug nanoparticles; Supercritical fluid processing

Indexed keywords

(E ,3E) PROCESS; (PL) PROPERTIES; AMPHOTERICIN B; AQUEOUS SOLUBILITY; AQUEOUS SOLUTIONS; CO SOLVENTS; CO-SOLVENTS; DELIVERY TECHNIQUES; DRUG FORMULATIONS; DRUG NANOPARTICLES; FLUID PROCESSING; LIQUID SOLVENT; NANO SCALING; NANO-SIZED; NANOSIZING; PRESENCE OF WATER; RAPID EXPANSION; STABLE SUSPENSIONS; SUPER-CRITICAL; SUPERCRITICAL CARBON DIOXIDE (SC CO2); SUPERCRITICAL SOLUTIONS; TRADITIONAL METHODS;

CARBON DIOXIDE; CARBON DIOXIDE PROCESS; CHEMOTHERAPY; DIMETHYL SULFOXIDE; DRUG DOSAGE; EFFLUENT TREATMENT; FARM BUILDINGS; FLUIDS; INDUSTRIAL WASTE TREATMENT; METAL CASTING; METHANOL; NANOPARTICLES; NANOSTRUCTURED MATERIALS; NANOSTRUCTURES; NANOTECHNOLOGY; OFFSHORE OIL WELL PRODUCTION; PHOTORESISTS; POLYMERS; SOLUBILITY; SOLUTIONS; SUPERCRITICAL FLUID EXTRACTION; SUPERCRITICAL FLUIDS; SUSPENSIONS (COMPONENTS); TERNARY SYSTEMS; WELL STIMULATION;

DRUG DELIVERY;

AMPHOTERICIN B; NANOMATERIAL;

ARTICLE; CHEMISTRY; COLLOID; CONFORMATION; CRYSTALLIZATION; DRUG FORMULATION; MACROMOLECULE; MATERIALS TESTING; METHODOLOGY; NANOTECHNOLOGY; PARTICLE SIZE; PHARMACEUTICS; SOLUTION AND SOLUBILITY; SUPERCRITICAL FLUID CHROMATOGRAPHY; SURFACE PROPERTY; ULTRASTRUCTURE;

AMPHOTERICIN B; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, SUPERCRITICAL FLUID; COLLOIDS; CRYSTALLIZATION; DRUG COMPOUNDING; MACROMOLECULAR SUBSTANCES; MATERIALS TESTING; MOLECULAR CONFORMATION; NANOSTRUCTURES; NANOTECHNOLOGY; PARTICLE SIZE; SOLUTIONS; SURFACE PROPERTIES; TECHNOLOGY, PHARMACEUTICAL;

EID: 34548172284     PISSN: 15334880     EISSN: None     Source Type: Journal    
DOI: 10.1166/jnn.2007.449     Document Type: Article

References (33)

1. C. A. Lipinski, Am. Pharm. Rev. 5, 82 (2002).
2. R. H. Muller, C. Jacobs, and O. Kayser, Adv. Drug. Deliv. Rev. 47, 3 (2001).
3. M. A. Sande and G. L. Mandell, The Pharmacological Basis of Therapeutics, edited by A. G. Gilman, L. S. Goodman, and A. Gilman, MacMillan, New York (1980), p. 1233.
4. S. Hansel and J. Bolard, Trends Pharmacol. Sci. 17, 445 (1996).
5. H. A. Gallis, R. H. Drew, and W. W. Pickard, Rev. Infect. Dis. 12, 308 (1990).
6. J. Minones, Jr., P. Dynarowicz-Latka, O. Conde, J. Minones, E. Iribarnegaray, and M. Casas, Colloidal and Surfaces B: Biointer-faces 29, 205 (2003).
7. R. L. Juliano, G. Lopez-Berestein, R. Hopfer, R. Mehta, K. Mehta, and K. Mills, Ann. NY Acad. Sci. 446, 390 (1985).
8. H. Fukui, T. Koike, A. Saheki, S. Sonoke, and J. Seki, Int. J. Pharm. 265, 37 (2003).
9. A. J. Atkinson and J. E. Bennett, Antimicrob. Agents Chemother. 13, 271 (1978).
10. (a) O. Kayser, Int. J. Pharm. 214, 83 (2001);
11. (b) O. Kayser, C. Olbrich, V. Yardley, A. F. Kiderlen, and S. L. Croft, Int. J. Pharm. 254, 73 (2003).
12. (a) Y.-P. Sun and H. W. Rollins, Chem. Phys. Lett. 288, 585 (1998);
13. (b) Y.-P. Sun, R. Guduru, F. Lin, and T. Whiteside, Ind. Eng. Chem. Res. 39, 4663 (2000).
14. (a) Y.-P. Sun, H. W. Rollins, and R. Guduru, Chem. Mater 11, 7 (1999);
15. (b) M. J. Meziani and Y.-P. Sun, J. Am. Chem. Soc. 125, 8015 (2003).
16. (a) M. J. Meziani, P. Pathak, R. Hurezeanu, M. C. Thies, R. M. Enick, and Y.-P. Sun, Angew. Chem. Int. Ed. 43, 704 (2004);
17. (b) Y.-P. Sun, M. J. Meziani, P. Pathak, and L. Qu, Chem. Eur. J. 11, 1366 (2005).
18. (a) P. Pathak, M. J. Meziani, T. Desai, and Y.-P. Sun, J. Am. Chem. Soc. 126, 10842 (2004);
19. (b) P. Pathak, M. J. Meziani, and Y.-P. Sun, Expert. Opin. Drug Deliv. 2, 747 (2005);
20. (c) P. Pathak, M. J. Meziani, T. Desai, and Y.-P. Sun, J. Supercrit. Fluids 37, 279 (2006).
21. M. J. Meziani and Y.-P. Sun, Langmuir 18, 3787 (2002).
22. S. Jaarmo, M. RantakyläO. Aaltonen, Proc. 4th Int. Symp. Supercrit. Fluids, edited by S. Saito and K. Arai (1997), p. 263.
23. (a) P. York, PSTT 2, 430 (1999);
24. (b) B. Y. Shekunov and P. York, J. Crystal Growth 211, 122 (2000).
25. (a) D. Andes, Antimicrob. Agents Chemother. 47, 1179 (2003).
26. (b) I. Bekersky, R. M. Fielding, D. E. Dressler, J. W. Lee, D. N. Buell, and T. J. Walsh, Antimicrob. Agents Chemother. 46, 834 (2002).
27. M. E. Klepser, E. J. Wolfe, R. N. Jones, C. H. Nightingale, and M. A. Pfaller, Antimicrob. Agents Chemother. 41, 1392 (1997).
28. A. Imhof, R. B. Walter, and A. Schaffner, Clin. Infect. Dis. 36, 943 (2003).
29. R. E. Lewis and N. P. Wiederhold, Clin. Infect. Dis. 37, 871 (2003), and the references therein.
30. H. G. Brittain (ed.), Polymorphism in Pharmaceutical Solids, Marcel Dekker, New York, USA (1999).
31. B. C. Hancock and M. Parks, Pharm. Res. 17, 397 (2000).
32. A. A. Elamin, C. Ahlneck, G. Alderborn, and C. Nystrom, Int. J. Pharm. 111, 159 (1994).
33. J. E. Kipp, Int. J. Pharm. 284, 109 (2004).